Skip to main content
Erschienen in: Irish Journal of Medical Science (1971 -) 2/2016

14.05.2015 | Original Article

Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy

verfasst von: E. M. Quinn, C. Fleming, M. J. O’Sullivan

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background/aims

Adjuvant endocrine therapy for at least 5 years improves oncological outcomes in oestrogen receptor-positive breast cancer. Adherence rates to prescribed endocrine therapy are low and the search for modifiable causes of this continues. The aim of this study was to assess adherence rates in an Irish cohort of breast cancer patients prescribed adjuvant endocrine therapy and to assess modifiable factors associated with suboptimal adherence.

Methods

A cross-sectional anonymous survey was performed on 261 patients currently prescribed endocrine therapy. Data were collected regarding demographics, treatment, social and emotional factors and medication side effects. Each patient completed a medication adherence score and provided information about discontinuation of therapy and reasons for same.

Results

Only 67.8 % of patients assessed demonstrated complete medication adherence on the medication adherence scale. Twenty-nine patients (10.9 %) permanently stopped taking their prescribed endocrine therapy. Suboptimal adherence was more likely in younger patients (p < 0.001), those in employment (p = 0.005), those who experienced side effects (p = 0.006), those who perceived themselves to have low levels of emotional support (p < 0.001) and those who use the internet to read about their illness (p = 0.003).

Conclusions

Endocrine therapy adherence is suboptimal in almost one-third of patients in our cohort. Appropriate assessment and management of side effects and negative emotions, combined with direction of patients to accurate internet sources of information, could help improve endocrine therapy adherence in women with early-stage breast cancer.
Literatur
1.
Zurück zum Zitat Early Breast Cancer Trialists’ Collabroative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451CrossRef Early Breast Cancer Trialists’ Collabroative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351(9114):1451CrossRef
2.
Zurück zum Zitat Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805CrossRefPubMedPubMedCentral Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Gray R, Rea D, Handley K et al (2013) aTTom: Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6593 women with early breast cancer. J Clin Oncol 31(suppl):abstr5 Gray R, Rea D, Handley K et al (2013) aTTom: Long term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6593 women with early breast cancer. J Clin Oncol 31(suppl):abstr5
4.
Zurück zum Zitat Allred DC, Anderson SJ, Paik S et al (2012) Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol 30(12):1268–1273CrossRefPubMedPubMedCentral Allred DC, Anderson SJ, Paik S et al (2012) Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol 30(12):1268–1273CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Santen RJ, Santner S, Davis B et al (1978) Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 47:1257–1265CrossRefPubMed Santen RJ, Santner S, Davis B et al (1978) Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 47:1257–1265CrossRefPubMed
6.
Zurück zum Zitat Jonat W, Howell A, Blomqvist C et al (1996) A randomised trial comparing two doses of the new selective aromatase inhibitor (“Arimidex”) with megestrol acetate in postmenopausal women with advanced breast cancer. Eur J Cancer 32A:404–412CrossRefPubMed Jonat W, Howell A, Blomqvist C et al (1996) A randomised trial comparing two doses of the new selective aromatase inhibitor (“Arimidex”) with megestrol acetate in postmenopausal women with advanced breast cancer. Eur J Cancer 32A:404–412CrossRefPubMed
7.
Zurück zum Zitat Buzdar AU, Jones SE, Vogel CL et al; The Arimidex Study Group (1997) A Phase III trial comparing anastrozole (1 and 10mg), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast cancer. Cancer (Phila.) 79:730–739CrossRef Buzdar AU, Jones SE, Vogel CL et al; The Arimidex Study Group (1997) A Phase III trial comparing anastrozole (1 and 10mg), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast cancer. Cancer (Phila.) 79:730–739CrossRef
8.
Zurück zum Zitat Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60CrossRefPubMed Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60CrossRefPubMed
9.
Zurück zum Zitat Mamounas E, Lembersky B, Jeong JH et al (2006) NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 7(5):416CrossRefPubMed Mamounas E, Lembersky B, Jeong JH et al (2006) NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 7(5):416CrossRefPubMed
10.
Zurück zum Zitat Barron T, Cahir C, Sharp L, Bennett K (2013) A nested case-control study of adjuvant hormonal therapy persistence and compliance and early breast cancer recurrence in women with stage I–III breast cancer. Br J Cancer 109:1513CrossRefPubMedPubMedCentral Barron T, Cahir C, Sharp L, Bennett K (2013) A nested case-control study of adjuvant hormonal therapy persistence and compliance and early breast cancer recurrence in women with stage I–III breast cancer. Br J Cancer 109:1513CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71(1–2):1PubMed Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71(1–2):1PubMed
12.
Zurück zum Zitat Stanton AL, Petrie KJ, Partridge AH (2014) Contributors to non-adherence and non-persistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat 145(2):525CrossRefPubMed Stanton AL, Petrie KJ, Partridge AH (2014) Contributors to non-adherence and non-persistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat 145(2):525CrossRefPubMed
13.
Zurück zum Zitat Simon R, Latreille J, Matte C, Desjardins P, Bergeron E (2013) Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. Can J Surg 57(1):26CrossRef Simon R, Latreille J, Matte C, Desjardins P, Bergeron E (2013) Adherence to adjuvant endocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up. Can J Surg 57(1):26CrossRef
14.
Zurück zum Zitat Jacob Arriola KR, Mason TA, Bannon KA et al (2014) Modifiable risk factors for adherence to aduvant endcorine therapy among breast cancer patients. Patient Educ Couns 95(1):98CrossRefPubMed Jacob Arriola KR, Mason TA, Bannon KA et al (2014) Modifiable risk factors for adherence to aduvant endcorine therapy among breast cancer patients. Patient Educ Couns 95(1):98CrossRefPubMed
15.
Zurück zum Zitat Danilak M, Chambers CR (2013) Adherence to adjuvant endocrine therapy in women with breast cancer. J Oncol Pharm Pract 19(2):105CrossRefPubMed Danilak M, Chambers CR (2013) Adherence to adjuvant endocrine therapy in women with breast cancer. J Oncol Pharm Pract 19(2):105CrossRefPubMed
16.
Zurück zum Zitat Cluze C, Rey D, Huiart L et al (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer, determinants of interruptions vary over time. Ann Oncol 23(4):82CrossRef Cluze C, Rey D, Huiart L et al (2012) Adjuvant endocrine therapy with tamoxifen in young women with breast cancer, determinants of interruptions vary over time. Ann Oncol 23(4):82CrossRef
17.
Zurück zum Zitat Bender CM, Gentry AL, Brufsky AM et al (2014) Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum 41(3):274CrossRefPubMedPubMedCentral Bender CM, Gentry AL, Brufsky AM et al (2014) Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum 41(3):274CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Albert US, Zemlin C, Hadji P et al (2011) The impact of breast care nurses on patients’ satisfaction, understanding of the disease and adherence to adjuvant endocrine therapy. Breast Care (Basel) 6(3):221CrossRef Albert US, Zemlin C, Hadji P et al (2011) The impact of breast care nurses on patients’ satisfaction, understanding of the disease and adherence to adjuvant endocrine therapy. Breast Care (Basel) 6(3):221CrossRef
19.
Zurück zum Zitat Cuzick J, Sestak I, Forbes JF et al (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383(9922):1041–1048CrossRefPubMed Cuzick J, Sestak I, Forbes JF et al (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383(9922):1041–1048CrossRefPubMed
20.
Zurück zum Zitat Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24(1):67CrossRefPubMed Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24(1):67CrossRefPubMed
21.
Zurück zum Zitat Ziller V, Kyvernitakis I, Knoll D, Storch A, Hards O, Hadji P et al (2013) Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment—the COMPAS study. BMC Cancer 13:407CrossRefPubMedPubMedCentral Ziller V, Kyvernitakis I, Knoll D, Storch A, Hards O, Hadji P et al (2013) Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment—the COMPAS study. BMC Cancer 13:407CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Aiello Bowles EJ, Boudreau DM, Chubak J et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early stage breast cancer. J Oncol Pract 8(6):e149CrossRefPubMedPubMedCentral Aiello Bowles EJ, Boudreau DM, Chubak J et al (2012) Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early stage breast cancer. J Oncol Pract 8(6):e149CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Markkula A, Hietala M, Henningson M et al (2012) Clinical profiles predict early non-adherence to adjuvant endocrine treatment in a prospective breast cancer cohort. Cancer Prev Res (Phula) 5(5):735CrossRef Markkula A, Hietala M, Henningson M et al (2012) Clinical profiles predict early non-adherence to adjuvant endocrine treatment in a prospective breast cancer cohort. Cancer Prev Res (Phula) 5(5):735CrossRef
24.
Zurück zum Zitat Guth U, Myrick ME, Kilic N, Eppenberger-Castori S, Schmid SM et al (2012) Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat 131(2):491CrossRefPubMed Guth U, Myrick ME, Kilic N, Eppenberger-Castori S, Schmid SM et al (2012) Compliance and persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Res Treat 131(2):491CrossRefPubMed
25.
Zurück zum Zitat Dittmer C, Roeder K, Hoellen F et al (2011) Compliance to adjuvant therapy in breast cancer patients. Eur J Gynaecol Oncol 32(3):280PubMed Dittmer C, Roeder K, Hoellen F et al (2011) Compliance to adjuvant therapy in breast cancer patients. Eur J Gynaecol Oncol 32(3):280PubMed
26.
Zurück zum Zitat Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen. A lesson for oncologists. Cancer 109(5):832CrossRefPubMed Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen. A lesson for oncologists. Cancer 109(5):832CrossRefPubMed
27.
Zurück zum Zitat Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515CrossRefPubMedPubMedCentral Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Font R, Espinas JA, Gil-Gil M et al (2012) Prescription refill, patient self report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer 107(8):1249CrossRefPubMedPubMedCentral Font R, Espinas JA, Gil-Gil M et al (2012) Prescription refill, patient self report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer 107(8):1249CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Guth U, Huang DJ, Schotzau A et al (2008) Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 99(3):428CrossRefPubMedPubMedCentral Guth U, Huang DJ, Schotzau A et al (2008) Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 99(3):428CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and non-adherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120CrossRefPubMedPubMedCentral Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and non-adherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Visram H, Kanji F, Dent SF (2010) Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol 17(5):17PubMedPubMedCentral Visram H, Kanji F, Dent SF (2010) Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol 17(5):17PubMedPubMedCentral
32.
Zurück zum Zitat Xu S, Yang Y, Tao W et al (2012) Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res treat 136:495CrossRefPubMed Xu S, Yang Y, Tao W et al (2012) Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res treat 136:495CrossRefPubMed
33.
Zurück zum Zitat Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G et al (2013) Adherence to adjuvant hormonal therapy and it relationship to breast cancer recurrence and survival among low income women. Am J Clin Oncol 36(2):181CrossRefPubMedPubMedCentral Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G et al (2013) Adherence to adjuvant hormonal therapy and it relationship to breast cancer recurrence and survival among low income women. Am J Clin Oncol 36(2):181CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Carlson JJ, Roth JA (2013) The impact of the oncotype DX breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat 141(1):13–22CrossRefPubMedPubMedCentral Carlson JJ, Roth JA (2013) The impact of the oncotype DX breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat 141(1):13–22CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Guiliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569CrossRef Guiliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6):569CrossRef
37.
Zurück zum Zitat Sert F, Ozsaran Z, Eser E et al (2013) Quality of life assessment in women with breast cancer: a prospective study including hormonal therapy. J Breast Cancer 16(2):220CrossRef Sert F, Ozsaran Z, Eser E et al (2013) Quality of life assessment in women with breast cancer: a prospective study including hormonal therapy. J Breast Cancer 16(2):220CrossRef
38.
Zurück zum Zitat Ediger JP, Walker JR, Graff L et al (2007) Predictors of Medication adherence in inflammatory bowel disease. Am J Gastroenterol 102:1417CrossRefPubMed Ediger JP, Walker JR, Graff L et al (2007) Predictors of Medication adherence in inflammatory bowel disease. Am J Gastroenterol 102:1417CrossRefPubMed
39.
Zurück zum Zitat Kiley DJ, Lam CS, Pollak R (1993) A study of treatment compliance following kidney transplantation. Transplantation 55(1):51–56CrossRefPubMed Kiley DJ, Lam CS, Pollak R (1993) A study of treatment compliance following kidney transplantation. Transplantation 55(1):51–56CrossRefPubMed
40.
Zurück zum Zitat Henry NL, Azzouz F, Desta Z et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early breast cancer. J Clin Oncol 30(9):936CrossRefPubMedPubMedCentral Henry NL, Azzouz F, Desta Z et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early breast cancer. J Clin Oncol 30(9):936CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Wouters H, Maatman GA, Van Dijk L et al (2013) Trade off preferences regarding adjuvant endocrine therapy among women with estrogen receptor positive breast cancer. Ann Oncol 24(9):2324CrossRefPubMed Wouters H, Maatman GA, Van Dijk L et al (2013) Trade off preferences regarding adjuvant endocrine therapy among women with estrogen receptor positive breast cancer. Ann Oncol 24(9):2324CrossRefPubMed
42.
Zurück zum Zitat Cuzick J, Sestak I, Cella D et al (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12):1143 Cuzick J, Sestak I, Cella D et al (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12):1143
43.
Zurück zum Zitat Van de Poll-Franse LV, van Eenbergen MC (2008) Internet use by cancer survivors: current use and future wishes. Support Care Cancer 16(10):1189e95 Van de Poll-Franse LV, van Eenbergen MC (2008) Internet use by cancer survivors: current use and future wishes. Support Care Cancer 16(10):1189e95
44.
Zurück zum Zitat Castleton K, Fong T, Wang-Gillam A et al (2011) A survey of internet utilization among patients with cancer. Support Care Cancer 19(8):1183–1190CrossRefPubMed Castleton K, Fong T, Wang-Gillam A et al (2011) A survey of internet utilization among patients with cancer. Support Care Cancer 19(8):1183–1190CrossRefPubMed
45.
Zurück zum Zitat McHugh SM, Corrigan M, Morney N et al (2011) A quantitative assessment of changing trends in internet usage for cancer information. World J Surg 35(2):253CrossRefPubMed McHugh SM, Corrigan M, Morney N et al (2011) A quantitative assessment of changing trends in internet usage for cancer information. World J Surg 35(2):253CrossRefPubMed
46.
Zurück zum Zitat Quinn EM, Corrigan M, McHugh SM et al (2012) Breast cancer information on the internet: analysis of accessibility and accuracy. Breast 21(4):514CrossRefPubMed Quinn EM, Corrigan M, McHugh SM et al (2012) Breast cancer information on the internet: analysis of accessibility and accuracy. Breast 21(4):514CrossRefPubMed
47.
Zurück zum Zitat Neven P, Markopoulos C, Tanner M et al (2014) The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. Breast [Epub ahead of print] Neven P, Markopoulos C, Tanner M et al (2014) The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. Breast [Epub ahead of print]
48.
Zurück zum Zitat Hadji P, Blettenr M, Harbeck N et al (2013) The patient’s anastrazole compliance to therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information programme on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 24(6):1505CrossRefPubMed Hadji P, Blettenr M, Harbeck N et al (2013) The patient’s anastrazole compliance to therapy (PACT) program: a randomized, in-practice study on the impact of a standardized information programme on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 24(6):1505CrossRefPubMed
49.
Zurück zum Zitat von Blanckenburg P, Schuricht F, Albert US, Rief W, Nestoriuc Y et al (2013) Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer 18(13):426CrossRef von Blanckenburg P, Schuricht F, Albert US, Rief W, Nestoriuc Y et al (2013) Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer 18(13):426CrossRef
51.
Zurück zum Zitat Wang P, Benner J, Glynn R et al (2004) How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf 13(1):11–19CrossRefPubMed Wang P, Benner J, Glynn R et al (2004) How well do patients report noncompliance with antihypertensive medications?: a comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf 13(1):11–19CrossRefPubMed
52.
Zurück zum Zitat Garber M, Nau D, Erickson S, Aikens J, Lawrence J (2004) The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care 42(7):649–652CrossRefPubMed Garber M, Nau D, Erickson S, Aikens J, Lawrence J (2004) The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care 42(7):649–652CrossRefPubMed
Metadaten
Titel
Endocrine therapy adherence: a cross-sectional study of factors affecting adherence and discontinuation of therapy
verfasst von
E. M. Quinn
C. Fleming
M. J. O’Sullivan
Publikationsdatum
14.05.2015
Verlag
Springer London
Erschienen in
Irish Journal of Medical Science (1971 -) / Ausgabe 2/2016
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-015-1307-4

Weitere Artikel der Ausgabe 2/2016

Irish Journal of Medical Science (1971 -) 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.